Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

While we don’t see this purchase as significantly affecting Merck’s wide moat, it does help diversify the company's late-stage pipeline. Merck Posts Solid Q4 Results, but Heavy Investments in ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The 21st century pharmaceutical and biotech ... health was a comparatively late development. Merck in Germany was possibly the earliest company to move in this direction. Originating as a pharmacy ...

With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.45 Billion, which is 0.22x below the industry average, the company ... For Merck & Co in the ...

Merck & Company (MRK) Company Description: Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

(Reuters) - Merck has acquired Modifi Biosciences for ... New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively kill cancer ...